

iNOVACC

November 30, 2022 • vajiramandravi.com



About iNOVACC:

- It is developed by **Bharat Biotech International Limited.**
- It was developed in partnership with **Washington University, St Louis**, which had designed and developed the recombinant adenoviral vectored construct and evaluated in pre-clinical studies for efficacy.
- The approval is under Restricted Use in **Emergency Situation for ages 18 and above in India, for heterologous booster doses.**
- iNOVACC is a **recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein.**
- It is the world's first intranasal vaccine to receive both primary series and heterologous booster approval.
- The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops.
- It is stable at 2-8 degrees Celsius for easy storage and distribution.

Source : All India Radio

Source: <https://vajiramandravi.com/current-affairs/incovacc/>

© Vajiram & Ravi. For personal use only.